What do systematic reviews say?

2,261 questions · 2,280 findings · 114 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 856 · 37.5%GRADE not reported 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%

Deferasirox and deferoxamine vs deferoxamine

Satisfaction with treatment · people with transfusion‐dependent thalassemia

The review found no eligible studies for this question.

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox and deferoxamine vs deferoxamine

Adherence: Discontinuations · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 94 participants
Very low

Deferasirox and deferoxamine vs deferoxamine

AE: Serum creatinine increase · people with transfusion‐dependent thalassemia

The review found no eligible studies for this question.

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Combined deferasirox and deferiprone vs deferiprone and deferoxamine

Mortality at any time point · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Low

Combined deferasirox and deferiprone vs deferiprone and deferoxamine

Responder analysis · people with transfusion‐dependent thalassemia

The review found no eligible studies for this question.

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Combined deferasirox and deferiprone vs deferiprone and deferoxamine

Serum ferritin (ng/mL): mean change from baseline · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Very low

Combined deferasirox and deferiprone vs deferiprone and deferoxamine

LIC · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Low

Deferasirox vs deferoxamine

Change in LIC (mg Fe/g dw) evaluated by biopsy or SQUID · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 541 participants
Moderate

Combined deferasirox and deferiprone vs deferiprone and deferoxamine

Satisfaction · people with transfusion‐dependent thalassemia

The review found no eligible studies for this question.

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Combined deferasirox and deferiprone vs deferiprone and deferoxamine

Adherence: Discontinuations · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Very low

Combined deferasirox and deferiprone vs deferiprone and deferoxamine

Drug‐related AE: serum creatinine increased (≥ 33%) above baseline in 2 consecutive occasions · people with transfusion‐dependent thalassemia

It is very uncertain whether deferasirox and deferiprone changes drug‐related AE: serum creatinine increased (≥ 33%) above baseline… compared with deferiprone and deferoxamine (very low certainty).

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
RR 3 [0.32, 27.83]
1 study · 96 participants
Very low

Deferasirox vs placebo

Mortality at any time point · people with non‐transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 148 participants
Moderate

Deferasirox vs placebo

Responder analysis · people with non‐transfusion‐dependent thalassemia

The review found no eligible studies for this question.

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox vs placebo

Serum ferritin (ng/mL): mean change from baseline · people with non‐transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 154 participants
Moderate

Deferasirox vs placebo

LIC (mg Fe/g dry weight) evaluated by MRI R2: least squares mean change from baseline · people with non‐transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 159 participants
Moderate

Deferasirox vs placebo

Satisfaction with treatment · people with non‐transfusion‐dependent thalassemia

The review found no eligible studies for this question.

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox vs placebo

Adherence: Discontinuations · people with non‐transfusion‐dependent thalassemia

Deferasirox showed no clear difference in adherence: Discontinuations compared with placebo (low certainty).

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
RR 1.32 [0.5, 3.52]
1 study · 166 participants
Low

Deferasirox vs placebo

AE: abnormal serum creatinine (post‐baseline) · people with non‐transfusion‐dependent thalassemia

It is very uncertain whether deferasirox changes AE: abnormal serum creatinine (post‐baseline) compared with placebo (very low certainty).

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
RR 3.59 [0.19, 68.4]
1 study · 166 participants
Very low

Deferasirox vs deferoxamine

Participant satisfaction (very satisfied or satisfied) · people with transfusion‐dependent thalassemia

Deferasirox probably leads to higher satisfaction with treatment (very satisfied or satisfied):… compared with deferoxamine (moderate certainty).

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
RR 2.2 [1.89, 2.57]
1 study · 571 participants
Moderate

Deferasirox vs deferoxamine

Adherence: Discontinuations · people with transfusion‐dependent thalassemia

Deferasirox showed no clear difference in adherence: discontinuations compared with deferoxamine (low certainty).

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
RR 0.95 [0.6, 1.5]
8 studies · 1211 participants
Low